Lareta, Suraida .
HRN: 05-42-86 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/18/2023
CO-AMOXICLAV 625MG (TAB)
10/18/2023
11/01/2023
PO
625mg
BID
Uncomplicatdd Cystitis
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes